Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $2.7 million.

  • Prestige Consumer Healthcare's Share-based Compensation fell 439.79% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.9 million, marking a year-over-year decrease of 1012.26%. This contributed to the annual value of $11.2 million for FY2025, which is 2036.4% down from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Share-based Compensation is $2.7 million, which was down 439.79% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Share-based Compensation ranged from a high of $4.1 million in Q2 2023 and a low of $1.7 million during Q1 2022
  • Moreover, its 5-year median value for Share-based Compensation was $2.7 million (2025), whereas its average is $2.9 million.
  • In the last 5 years, Prestige Consumer Healthcare's Share-based Compensation surged by 10537.81% in 2022 and then plummeted by 4213.67% in 2024.
  • Prestige Consumer Healthcare's Share-based Compensation (Quarter) stood at $2.2 million in 2021, then rose by 8.91% to $2.4 million in 2022, then increased by 0.66% to $2.4 million in 2023, then rose by 16.99% to $2.9 million in 2024, then decreased by 4.4% to $2.7 million in 2025.
  • Its Share-based Compensation was $2.7 million in Q4 2025, compared to $1.8 million in Q3 2025 and $3.7 million in Q2 2025.